

**BEFORE THE  
BOARD OF PHARMACY  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA**

**In the Matter of the Accusation Against:**

**ACROTECH BIOPHARMA LLC,  
DBA ACROTECH BIOPHARMA INC.;  
ASHISH ANVEKAR, PRESIDENT;  
KIRAN NAGABANDHI, TRES/CFO;  
WILLIAM H. REISS, DRIC**

**Out of State Distributor License No. OSD 7659,**

**and**

**WILLIAM HERMAN REISS,**

**Designated Representative License No. EXC 26864,**

**Respondents.**

**Agency Case No. 7468**

**OAH No. 2023100078**

## DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order for Public Repeval is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on June 19, 2024.

It is so ORDERED on May 20, 2024.

BOARD OF PHARMACY  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA

By



Seung W. Oh, Pharm.D.  
Board President

1 ROB BONTA  
Attorney General of California  
2 KAREN R. DENVER  
Supervising Deputy Attorney General  
3 MALISSA N. SIEMANTEL  
Deputy Attorney General  
4 State Bar No. 240157  
1300 I Street, Suite 125  
5 P.O. Box 944255  
Sacramento, CA 94244-2550  
6 Telephone: (916) 210-7555  
Facsimile: (916) 324-5567  
7 *Attorneys for Complainant*

8  
9 **BEFORE THE**  
**BOARD OF PHARMACY**  
10 **DEPARTMENT OF CONSUMER AFFAIRS**  
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

13 **ACROTECH BIOPHARMA LLC,**  
14 **DBA ACROTECH BIOPHARMA INC.;**  
15 **ASHISH ANVEKAR, PRESIDENT;**  
16 **KIRAN NAGABANDHI, TRES/CFO;**  
17 **WILLIAM H. REISS, DRIC**  
279 Princeton Hightstown Rd., Ste. 103  
East Windsor, NJ 08520

18 **Out of State Distributor License No. OSD 7659**

19 **WILLIAM HERMAN REISS**  
279 Princeton Hightstown Rd, #103  
East Windsor, NJ 08563

20 **Designated Representative License No.**  
21 **EXC 26864**

22 Respondents.

Case No. 7468

OAH No. 2023100078

**STIPULATED SETTLEMENT AND  
DISCIPLINARY ORDER FOR  
PUBLIC REPROVAL AS TO  
RESPONDENT ACROTECH  
BIOPHARMA LLC, DBA ACROTECH  
BIOPHARMA INC. ONLY**

[Bus. & Prof. Code § 495]

23  
24 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-  
25 entitled proceedings that the following matters are true:

26 **PARTIES**

27 1. Anne Sodergren (Complainant) is the Executive Officer of the Board of Pharmacy  
28 (Board). She brought this action solely in her official capacity and is represented in this matter by

1 Rob Bonta, Attorney General of the State of California, by Malissa N. Siemantel, Deputy  
2 Attorney General.

3 2. Acrotech Biopharma LLC, doing business Acrotech Biopharma Inc. (Respondent  
4 Acrotech) is represented in this proceeding by attorney Michael A. Gawley, whose address is: 50  
5 California Street, 34th Floor, San Francisco, CA 94111.

6 **JURISDICTION**

7 3. On or about November 18, 2019, the Board issued Out of State Distributor License  
8 Number OSD 7659 to Respondent Acrotech. The Board's records indicate that Ashish Avenkar  
9 has been President since September 14, 2019, Krian Nagabandhi has been the Treasurer and  
10 Chief Financial Officer since September 14, 2019, and William H. Reiss (Respondent Reiss), is  
11 and has been the Designated Representative-in-Charge (DRIC) since November 23, 2022. The  
12 Out of State Distributor License was in full force and effect at all times relevant to the charges  
13 brought herein and will expire on November 1, 2025, unless renewed.

14 4. Accusation No. 7468 was filed before the Board and is currently pending against  
15 Respondent Acrotech. The Accusation and all other statutorily required documents were properly  
16 served on Respondent on May 15, 2023. Respondent Acrotech timely filed its Notice of Defense  
17 contesting the Accusation. A copy of Accusation No. 7468 is attached as exhibit A and  
18 incorporated herein by reference.

19 **ADVISEMENT AND WAIVERS**

20 5. Respondent Acrotech has carefully read, fully discussed with counsel, and  
21 understands the charges and allegations in Accusation No. 7468. Respondent Acrotech has also  
22 carefully read, fully discussed with counsel, and understands the effects of this Stipulated  
23 Settlement and Disciplinary Order for Public Repeval.

24 6. Respondent Acrotech is fully aware of its legal rights in this matter, including the  
25 right to a hearing on the charges and allegations in the Accusation; the right to be represented by  
26 counsel at its own expense; the right to confront and cross-examine the witnesses against them;  
27 the right to present evidence and to testify on its own behalf; the right to the issuance of  
28 subpoenas to compel the attendance of witnesses and the production of documents; the right to

1 reconsideration and court review of an adverse decision; and all other rights accorded by the  
2 California Administrative Procedure Act and other applicable laws.

3 7. Respondent Acrotech voluntarily, knowingly, and intelligently waives and gives up  
4 each and every right set forth above.

5 **CULPABILITY**

6 8. Respondent Acrotech admits the truth of each and every charge and allegation in  
7 Accusation No. 7468.

8 9. Respondent Acrotech agrees that its Out of State Distributor License is subject to  
9 discipline and they agree to be bound by the Disciplinary Order below.

10 **CONTINGENCY**

11 10. This stipulation shall be subject to approval by the Board of Pharmacy. Respondent  
12 Acrotech understands and agrees that counsel for Complainant and the staff of the Board of  
13 Pharmacy may communicate directly with the Board regarding this stipulation and settlement,  
14 without notice to or participation by Respondent or its counsel. By signing the stipulation,  
15 Respondent Acrotech understands and agrees that they may not withdraw its agreement or seek to  
16 rescind the stipulation prior to the time the Board considers and acts upon it. If the Board fails to  
17 adopt this stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary Order  
18 for Public Repeval shall be of no force or effect, except for this paragraph, it shall be  
19 inadmissible in any legal action between the parties, and the Board shall not be disqualified from  
20 further action by having considered this matter.

21 11. The parties understand and agree that Portable Document Format (PDF) and facsimile  
22 copies of this Stipulated Settlement and Disciplinary Order for Public Repeval, including PDF  
23 and facsimile signatures thereto, shall have the same force and effect as the originals.

24 12. This Stipulated Settlement and Disciplinary Order for Public Repeval is intended by  
25 the parties to be an integrated writing representing the complete, final, and exclusive embodiment  
26 of their agreement. It supersedes any and all prior or contemporaneous agreements,  
27 understandings, discussions, negotiations, and commitments (written or oral). This Stipulated  
28 Settlement and Disciplinary Order for Public Repeval may not be altered, amended, modified,

1 supplemented, or otherwise changed except by a writing executed by an authorized representative  
2 of each of the parties.

3 13. In consideration of the foregoing admissions and stipulations, the parties agree that  
4 the Board may, without further notice or formal proceeding, issue and enter the following  
5 Disciplinary Order:

6 **DISCIPLINARY ORDER**

7 IT IS HEREBY ORDERED that Out of State Distributor License No. OSD 7659 issued to  
8 Respondent Acrotech Biopharma LLC, doing business Acrotech Biopharma Inc., shall be  
9 publicly reprovved by the Board of Pharmacy under Business and Professions Code section 495 in  
10 resolution of Accusation No. 7468, attached as exhibit A.

11 **Cost Recovery.** No later than twelve (12) months from the effective date of the Decision,  
12 Respondent Acrotech shall pay \$5,756.25 to the Board for its costs associated with the  
13 investigation and enforcement of this matter pursuant to Business and Professions Code Section  
14 125.3. If Respondent Acrotech fails to pay the Board costs as ordered, Respondent Acrotech  
15 shall not be allowed to renew their Out of State Distributor License until Respondent Acrotech  
16 pays costs in full. In addition, the Board may enforce this order for payment of its costs in any  
17 appropriate court, in addition to any other rights the Board may have.

18 **VAWD Accreditation and Reports.** No later than 60 days from the effective date of the  
19 Decision, Respondent Acrotech shall provide to the Board proof of drug distributor accreditation  
20 by the Verified-Accredited Wholesale Distributors (VAWD) Program through the National  
21 Association of Boards of Pharmacy (NABP). Further, Respondent Acrotech shall submit to the  
22 Board, for three (3) years from the effective date of the Decision, any and all reports, including,  
23 but not limited to, inspection reports, issued to Respondent Acrotech by VAWD within five (5)  
24 days of Respondent Acrotech's receipt of the report(s).

25 **Full Compliance.** As a resolution of the charges in Accusation No. 7468, this stipulated  
26 settlement is contingent upon Respondent Acrotech's full compliance with all conditions of this  
27 Order. If Respondent Acrotech fails to satisfy any of these conditions, such failure to comply

28 ///

1 constitutes cause for discipline, including outright revocation, of Respondent Acrotech's Out of  
2 State Distributor License No. OSD 7659.

3 **ACCEPTANCE**

4 I, Ashish Anvekar, as President of Acrotech Biopharma LLC, doing business Acrotech  
5 Biopharma Inc., have carefully read the above Stipulated Settlement and Disciplinary Order for  
6 Public Repeval and have fully discussed it with my attorney, Michael A. Gawley. I, on behalf of  
7 Acrotech Biopharma LLC, doing business Acrotech Biopharma Inc., understand the stipulation  
8 and the effect it will have on the Out of State Distributor License. I am authorized to enter into  
9 this Stipulated Settlement and Disciplinary Order for Public Repeval on behalf of Acrotech  
10 Biopharma LLC, doing business Acrotech Biopharma Inc. Acrotech Biopharma LLC, doing  
11 business Acrotech Biopharma Inc., enters into this Stipulated Settlement and Disciplinary Order  
12 for Public Repeval voluntarily, knowingly, and intelligently, and agrees to be bound by the  
13 Decision and Order of the Board of Pharmacy.

14  
15 DATED: \_\_\_\_\_

\_\_\_\_\_   
ACROTECH BIOPHARMA LLC,  
DBA ACROTECH BIOPHARMA INC.,  
ASHISH ANVEKAR, PRESIDENT  
*Respondent*

16  
17  
18  
19 I have read and fully discussed with Ashish Anvekar as an authorized representative of  
20 Acrotech Biopharma LLC, doing business Acrotech Biopharma Inc., the terms and conditions and  
21 other matters contained in the above Stipulated Settlement and Disciplinary Order for Public  
22 Repeval. I approve its form and content.

23  
24 DATED: \_\_\_\_\_

\_\_\_\_\_   
MICHAEL A. GAWLEY  
*Attorney for Respondent*

25  
26 ///

27 ///

28 ///

1 constitutes cause for discipline, including outright revocation, of Respondent Acrotech's Out of  
2 State Distributor License No. OSD 7659.

3 **ACCEPTANCE**

4 I, Ashish Anvekar, as President of Acrotech Biopharma LLC, doing business Acrotech  
5 Biopharma Inc., have carefully read the above Stipulated Settlement and Disciplinary Order for  
6 Public Repeval and have fully discussed it with my attorney, Michael A. Gawley. I, on behalf of  
7 Acrotech Biopharma LLC, doing business Acrotech Biopharma Inc., understand the stipulation  
8 and the effect it will have on the Out of State Distributor License. I am authorized to enter into  
9 this Stipulated Settlement and Disciplinary Order for Public Repeval on behalf of Acrotech  
10 Biopharma LLC, doing business Acrotech Biopharma Inc. Acrotech Biopharma LLC, doing  
11 business Acrotech Biopharma Inc., enters into this Stipulated Settlement and Disciplinary Order  
12 for Public Repeval voluntarily, knowingly, and intelligently, and agrees to be bound by the  
13 Decision and Order of the Board of Pharmacy.

14  
15 DATED: 2/21/2024

Ashish Anvekar

Digitally signed by Ashish Anvekar  
DN: cn=Ashish Anvekar, o=Acrotech Biopharma, ou,  
email=aanvekar@acrotechbiopharma.com, c=US  
Date: 2024.02.21 15:44:00 -05'00'

16 ACROTECH BIOPHARMA LLC,  
17 DBA ACROTECH BIOPHARMA INC.,  
18 ASHISH ANVEKAR, PRESIDENT  
19 *Respondent*

20 I have read and fully discussed with Ashish Anvekar as an authorized representative of  
21 Acrotech Biopharma LLC, doing business Acrotech Biopharma Inc., the terms and conditions and  
22 other matters contained in the above Stipulated Settlement and Disciplinary Order for Public  
23 Repeval. I approve its form and content.

24 DATED: 2/26/2024



25 MICHAEL A. GAWLEY  
26 *Attorney for Respondent*

27 ///

28 ///

///



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**ENDORSEMENT**

The foregoing Stipulated Settlement and Disciplinary Order for Public Repeval is hereby respectfully submitted for consideration by the Board of Pharmacy of the Department of Consumer Affairs.

DATED:

Respectfully submitted,

ROB BONTA  
Attorney General of California  
KAREN R. DENVIR  
Supervising Deputy Attorney General

MALISSA N. SIEMANTEL  
Deputy Attorney General  
*Attorneys for Complainant*

SA2023300847  
37885527.docx


**ENDORSEMENT**

The foregoing Stipulated Settlement and Disciplinary Order for Public Reapproval is hereby respectfully submitted for consideration by the Board of Pharmacy of the Department of Consumer Affairs.

DATED: February 26, 2024

Respectfully submitted,

ROB BONTA  
Attorney General of California  
KAREN R. DENVIR  
Supervising Deputy Attorney General

  
Digitally signed by  
Malissa N. Siemantel  
Date: 2024.02.26  
11:55:11 -08'00'

MALISSA N. SIEMANTEL  
Deputy Attorney General  
*Attorneys for Complainant*

SA2023300847  
37885527.docx

**Exhibit A**

**Accusation No. 7468**

1 ROB BONTA  
Attorney General of California  
2 KAREN R. DENVER  
Supervising Deputy Attorney General  
3 MALISSA N. SIEMANTEL  
Deputy Attorney General  
4 State Bar No. 240157  
1300 I Street, Suite 125  
5 P.O. Box 944255  
Sacramento, CA 94244-2550  
6 Telephone: (916) 210-7555  
Facsimile: (916) 324-5567  
7 *Attorneys for Complainant*

8  
9 **BEFORE THE**  
**BOARD OF PHARMACY**  
10 **DEPARTMENT OF CONSUMER AFFAIRS**  
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

Case No. 7468

13 **ACROTECH BIOPHARMA LLC,**  
14 **DBA ACROTECH BIOPHARMA INC.;**  
15 **ASHISH ANVEKAR, PRESIDENT;**  
16 **KIRAN NAGABANDHI, TRES/CFO;**  
17 **WILLIAM H. REISS, DRIC**  
279 Princeton Hightstown Rd., Ste. 103  
East Windsor, NJ 08520

**ACCUSATION**

**Out of State Distributor License No. OSD 7659**

18 **WILLIAM HERMAN REISS**  
19 279 Princeton Hightstown Rd, #103  
East Windsor, NJ 08563

20 **Designated Representative License No.**  
21 **EXC 26864**

22 Respondents.

23  
24  
25 **PARTIES**

26 1. Anne Sodergren (Complainant) brings this Accusation solely in her official capacity  
27 as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs (Board).

28 ///

1           2.     On or about November 18, 2019, the Board issued Out of State Distributor License  
2     Number OSD 7659 to Acrotech Biopharma LLC, doing business Acrotech Biopharma Inc.  
3     (Respondent Acrotech). The Board’s records indicate that Ashish Avenkar has been President  
4     since September 14, 2019, Krian Nagabandhi has been the Treasurer and Chief Financial Officer  
5     since September 14, 2019, and William H. Reiss (Respondent Reiss), is and has been the  
6     Designated Representative-in-Charge (DRIC) since November 22, 2023. The Out of State  
7     Distributor License was in full force and effect at all times relevant to the charges brought herein  
8     and will expire on November 1, 2023, unless renewed.

9           3.     On or about November 23, 2022, the Board issued Designated Representative License  
10     Number EXC 26864 to Respondent Reiss. The Designated Representative License will expire on  
11     November 1, 2023, unless renewed.

### **JURISDICTION**

12           4.     This Accusation is brought before the Board under the authority of the following  
13     laws. All section references are to the Business and Professions Code (Code) unless otherwise  
14     indicated.

15           5.     Code section 118, subdivision (b), provides that the suspension, expiration, surrender,  
16     cancellation of a license shall not deprive the Board of jurisdiction to proceed with a disciplinary  
17     action during the period within which the license may be renewed, restored, reissued or  
18     reinstated.

19           6.     Code section 4300, subdivision (a), provides that every license issued by the Board  
20     may be suspended or revoked.

21           7.     Code section 4300.1 states:

22                 The expiration, cancellation, forfeiture, or suspension of a board-issued license  
23                 by operation of law or by order or decision of the board or a court of law, the  
24                 placement of a license on a retired status, or the voluntary surrender of a license by a  
25                 licensee shall not deprive the board of jurisdiction to commence or proceed with any  
26                 investigation of, or action or disciplinary proceeding against, the licensee or to render  
27                 a decision suspending or revoking the license.

27     ///

28     ///

1 **STATUTORY AND REGULATORY PROVISIONS**

2 8. Code section 4022.5 states:

3 (a) “Designated representative” means an individual to whom a license has  
4 been granted pursuant to Section 4053. A pharmacist fulfilling the duties of Section  
4053 shall not be required to obtain a license as a designated representative.

5 (b) “Designated representative-in-charge” means a designated representative or  
6 designated representative-reverse distributor, or a pharmacist licensed in the home  
7 state proposed by a wholesaler or veterinary food-animal drug retailer and approved  
8 by the board as the supervisor or manager responsible for ensuring the wholesaler’s  
or veterinary food-animal drug retailer’s compliance with all state and federal laws  
and regulations pertaining to practice in the applicable license category.

9 9. Code section 4053, subdivision (a), states<sup>1</sup>:

10 Notwithstanding Section 4051, the board may issue a license as a designated  
11 representative to provide sufficient and qualified supervision in a wholesaler or  
12 veterinary food-animal drug retailer. The designated representative shall protect the  
public health and safety in the handling, storage, and shipment of dangerous drugs  
and dangerous devices in the wholesaler or veterinary food-animal drug retailer.

13 10. Code section 4161 states, in pertinent part:

14 (a) A person located outside this state that (1) ships, sells, mails, warehouses,  
15 distributes, or delivers dangerous drugs or dangerous devices into this state or (2)  
16 sells, brokers, warehouses, or distributes dangerous drugs or devices within this state  
shall be considered a nonresident wholesaler or a nonresident third-party logistics  
provider.

17 (b) A nonresident wholesaler or nonresident third-party logistics provider shall  
18 be licensed by the board prior to shipping, selling, mailing, warehousing, distributing,  
19 or delivering dangerous drugs or dangerous devices to a site located in this state or  
selling, brokering, warehousing, or distributing dangerous drugs or devices within  
this state.

20 ...

21 (i) (1) The board shall not issue or renew a nonresident wholesaler license until  
22 the nonresident wholesaler identifies a designated representative-in-charge and  
23 notifies the board in writing of the identity and license number of the designated  
representative-in-charge.

24 ...

25 (j) The designated representative-in-charge shall be responsible for the  
26 compliance of the nonresident wholesaler with state and federal laws governing  
wholesalers. The responsible manager shall be responsible for the compliance of the  
27 nonresident third-party logistics provider’s place of business with state and federal  
laws governing third-party logistics providers. A nonresident wholesaler or

28 <sup>1</sup> Effective January 1, 2022, Code section 4053 was amended. However, the amendment  
did not change the language of subdivision (a).

1 nonresident third-party logistics provider shall identify and notify the board of a new  
2 designated representative-in-charge or responsible manager within 30 days of the date  
3 that the prior designated representative-in-charge or responsible manager ceases to be  
4 the designated representative-in-charge or responsible manager.

5 ...

6 11. Code section 4301 states, in pertinent part:

7 The board shall take action against any holder of a license who is guilty of  
8 unprofessional conduct or whose license has been issued by mistake. Unprofessional  
9 conduct includes, but is not limited to, any of the following:

10 ...

11 (o) Violating or attempting to violate, directly or indirectly, or assisting in or  
12 abetting the violation of or conspiring to violate any provision or term of this chapter  
13 or of the applicable federal and state laws and regulations governing pharmacy,  
14 including regulations established by the board or by any other state or federal  
15 regulatory agency.

16 (p) Actions or conduct that would have warranted denial of a license.

17 ...

18 12. Code section 4307, subdivision (a), states:

19 Any person who has been denied a license or whose license has been revoked  
20 or is under suspension, or who has failed to renew his or her license while it was  
21 under suspension, or who has been a manager, administrator, owner, member, officer,  
22 director, associate, partner, or any other person with management or control of any  
23 partnership, corporation, trust, firm, or association whose application for a license has  
24 been denied or revoked, is under suspension or has been placed on probation, and  
25 while acting as the manager, administrator, owner, member, officer, director,  
26 associate, partner, or any other person with management or control had knowledge of  
27 or knowingly participated in any conduct for which the license was denied, revoked,  
28 suspended, or placed on probation, shall be prohibited from serving as a manager,  
administrator, owner, member, officer, director, associate, partner, or in any other  
position with management or control of a licensee as follows:

(1) Where a probationary license is issued or where an existing license is placed  
on probation, this prohibition shall remain in effect for a period not to exceed five  
years.

(2) Where the license is denied or revoked, the prohibition shall continue until  
the license is issued or reinstated.

13. California Code of Regulations, title 16, (Regulations) section 1781, subdivision (a),  
states:

A registered pharmacist, or a designated representative certified in accordance  
with Section 4053 of the Business and Professions Code, shall be present and in  
control of a manufacturer's or wholesaler's licensed premises during the conduct of  
business.

1 **COST RECOVERY**

2 14. Section 125.3 of the Code provides, in pertinent part, that the Board may request the  
3 administrative law judge to direct a licensee found to have committed a violation or violations of  
4 the licensing act to pay a sum not to exceed the reasonable costs of the investigation and  
5 enforcement of the case, with failure of the licensee to comply subjecting the license to not being  
6 renewed or reinstated. If a case settles, recovery of investigation and enforcement costs may be  
7 included in a stipulated settlement.

8 **FACTUAL ALLEGATIONS**

9 15. On or about October 27, 2022, the Board received an “Application for Change of  
10 Designated Representative-in-Charge (DRIC)” (the application) for Respondent Acrotech. The  
11 application was signed on October 18, 2022, under penalty of perjury by Kiran K. Nagabandi, as  
12 the corporate officer, and William Herman Reiss, as the new DRIC. The application stated that  
13 Steve Lucas stopped acting as DRIC for Acrotech on November 3, 2021, and that Respondent  
14 Reiss started acting as the new DRIC on November 4, 2021. Respondent Reiss was not licensed  
15 as a Designated Representative at that time.

16 16. On or about November 23, 2022, the Board issued Designated Representative License  
17 Number EXC 26864 to Respondent Reiss. The Designated Representative License will expire on  
18 November 1, 2023, unless renewed.

19 **FIRST CAUSE FOR DISCIPLINE**

20 **(Failure to Have a Designated Representative-in-Charge)**

21 17. Respondent Acrotech is subject to disciplinary action under Code section 4301,  
22 subdivisions (o) and (p), in conjunction with Code section 4161 and Regulations section 1781,  
23 subdivision (a), in that on or about and between November 4, 2021, and November 22, 2022,  
24 Respondent Acrotech failed to have a DRIC who was properly licensed in accordance with Code  
25 sections 4022.5 and 4161, as set forth in paragraphs 15 and 16, above.

26 ///

27 ///

28 ///



1 **SECOND CAUSE FOR DISCIPLINE**

2 **(Failure to Notify Board of Change in Designated Representative-in-Charge)**

3 18. Respondent Acrotech is subject to disciplinary action under Code section 4301,  
4 subdivisions (o) and (p), in conjunction with Code section 4161, subdivision (j), in that  
5 Respondent Acrotech failed to notify the Board of a new, properly licensed DRIC within 30 days  
6 of the date that the prior DRIC ceased to be the DRIC, as set forth in paragraph 15, above.

7 **THIRD CAUSE FOR DISCIPLINE**

8 **(Acting as a Designated Representative-in-Charge without a License)**

9 19. Respondent Reiss is subject to disciplinary action under Code section 4301,  
10 subdivisions (o) and (p), in conjunction with Code sections 4053 and 4161, and Regulations  
11 section 1781, subdivision (a), in that Respondent Reiss acted as a DRIC without having a valid  
12 Designated Representative License, as set forth in paragraphs 15 and 16, above.

13 **DISCIPLINE CONSIDERATIONS**

14 20. To determine the degree of discipline, if any, to be imposed on Respondent Acrotech,  
15 Complainant alleges that on or about August 24, 2021, in a prior action, the Board of Pharmacy  
16 issued Citation Number CI 2020 91731 and ordered Respondent Acrotech to pay a civil penalty in  
17 the amount of \$750. The circumstances are that Respondent Acrotech failed to notify the Board  
18 in writing within 30 days of the date when a DRIC ceased to act as the DRIC when Respondent  
19 Acrotech notified the Board of the change in DRIC 434 days later. Further, Respondent Acrotech  
20 operated without a DRIC for 189 days. That Citation is now final.

21 **OTHER MATTERS**

22 21. Pursuant to Code section 4307, if discipline is imposed on Out of State Distributor  
23 License Number OSD 7659 issued to Acrotech Biopharma LLC, doing business as Acrotech  
24 Biopharma Inc., it shall be prohibited from serving as a manager, administrator, owner, member,  
25 officer, director, associate, partner, or in any other position with management or control of a  
26 licensee for five years if Out of State Distributor License Number OSD 7659 is placed on  
27 probation or until Out of State Distributor License Number OSD 7659 is reinstated if it is  
28 revoked.



1           3.     Ordering Acrotech Biopharma LLC, doing business as Acrotech Biopharma Inc., and  
2 William Herman Reiss to pay the Board of Pharmacy the reasonable costs of the investigation and  
3 enforcement of this case, pursuant to Business and Professions Code section 125.3;

4           4.     Prohibiting Acrotech Biopharma LLC, doing business as Acrotech Biopharma Inc.,  
5 from serving as a manager, administrator, owner, member, officer, director, associate, partner, or  
6 in any other position with management or control of a licensee for five years if Out of State  
7 Distributor License Number OSD 7659 is placed on probation or until Out of State Distributor  
8 License Number OSD 7659 issued to Acrotech Biopharma LLC, doing business as Acrotech  
9 Biopharma Inc., is reinstated if it is revoked;

10          5.     Prohibiting Krian Nagabandhi from serving as a manager, administrator, owner,  
11 member, officer, director, associate, partner, or in any other position with management or control  
12 of a licensee for five years if Out of State Distributor License Number OSD 7659 is placed on  
13 probation or until Out of State Distributor License Number OSD 7659 issued to Acrotech  
14 Biopharma LLC, doing business as Acrotech Biopharma Inc., is reinstated if it is revoked;

15          6.     Prohibiting William Herman Reiss from serving as a manager, administrator, owner,  
16 member, officer, director, associate, partner, or in any other position with management or control  
17 of a licensee for five years if Out of State Distributor License Number OSD 7659 is placed on  
18 probation or until Out of State Distributor License Number OSD 7659 issued to Acrotech  
19 Biopharma LLC, doing business as Acrotech Biopharma Inc., is reinstated if it is revoked and,

20          7.     Taking such other and further action as deemed necessary and proper.

21  
22  
23 DATED: 5/8/2023

Digitally signed by Sodergren,  
Anne@DCA  
Date: 2023.05.08 08:03:45  
-07'00'

ANNE SODERGREN  
Executive Officer  
Board of Pharmacy  
Department of Consumer Affairs  
State of California  
*Complainant*

24  
25  
26  
27  
28 SA2023300847  
37111434.docx